The proteomic analysis elucidated that ANXA5, GPM6A, VGF, and ACTZ could distinguish AD EVs from controls with high accuracy, thus providing novel biomarkers for AD (Muraoka et al., 2020c). The gene discussed is ANXA5; the disease is Alzheimer disease.